Development of nano-tricalcium phosphate/polycaprolactone/platelet-rich plasma biocomposite for bone defect regeneration

Abstract

Nano-tricalcium phosphate (n-TCP) is an osteoconductive substance which, like polycaprolactone (PCL), has been used for clinical purposes for many years; It has now been licensed for a range of products for clinical and medication distribution. This research aimed to examine the effects of platelet-rich plasma on mesenchymal stem cell proliferation and osteogenic differentiation. Thus, we decided to examine the in vitro and in vivo actions of PRP-treated porous biocomposite scaffolds based on nano-tricalcium phosphate- polycaprolactone (n-TCP-PCL/PRP). The prepared samples were described utilizing FTIR, XRD, and SEM. MTT has measured the cytotoxicity of the biocomposite scaffolds. After two weeks of cell seeding, Alizarin red staining confirmed bone mineral formation by MSCs cells. Moreover, from day 4 to day 7, n-TCP-PCL/PRP biocomposite scaffold improved the expresses of bone marker genes. Platelet-rich plasma (PRP) in conjunction with nano-tricalcium phosphate- polycaprolactone (n-TCP-PCL) biocomposite scaffold is beneficial for the regeneration and stability of the freshly developed bone tissue.

Keywords

• Biocomposite
• Bone regeneration
• Platelet-rich plasma
• Tricalcium phosphate